
    
      Protocol number: TLCTLC388A1008

      Primary objective:

      To evaluate the safety and tolerability, including maximum tolerated dose (MTD) and
      dose-limiting toxicity (DLT), of Lipotecan based concurrent chemoradiotherapy (CCRT) in
      patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT)
      unsuitable for local treatment.

      Secondary Objective:

      The secondary objective is to explore the efficacy of Lipotecan based CCRT in patients with
      HCC and PVTT and the effect on quality of life.
    
  